# DESCRIPTION

## GOVERNMENT FUNDING

- acknowledge government funding

## FIELD

- define field of invention

## BACKGROUND

- discuss limitations of current treatments

## SUMMARY

- introduce targeted nanoparticles
- describe composition embodiments
- describe method embodiments
- summarize other aspects of invention

## DETAILED DESCRIPTION

- introduce targeted nanoparticles
- describe application of stimulus to activate targeting moiety
- explain delivery of particles to specific locations
- describe particles with controllable surface features
- illustrate example of cell-penetrating peptide attached to particle
- describe cleavable entity and targeting moiety
- explain attachment of activatable agent to polymer
- describe various targeting moieties, including peptides and antibodies
- list examples of cell-penetrating peptides
- describe cleavable entity, including photocleavable entities
- explain association of cleavable entity with core region of particle
- describe particle composition, including core and shell regions
- explain diameter of particle, including nanoparticles
- describe formation of particle from polymer
- explain core-shell structure, including hydrophobic and hydrophilic regions
- describe examples of hydrophilic and hydrophobic polymers
- explain ratio of molecular weights of polymers
- describe methods for binding cleavable entity and targeting moiety
- explain binding of activatable agent to polymer
- describe activatable agent concentration
- describe targeting moiety and cleavable entity concentration
- describe drug presence and location
- list examples of drugs for eye treatment
- list examples of drugs for cancer treatment
- describe particle administration and targeting
- describe photocleavage of cleavable entity
- describe light application parameters
- describe light frequency and duration
- describe preferential targeting of abnormally-growing blood vessels
- describe composition applications
- describe composition administration methods
- describe composition introduction to subject
- describe composition dose and administration frequency
- describe pharmaceutically acceptable carriers and formulations
- describe implantable drug delivery systems
- describe liposome and polymer release systems
- describe carrier materials and properties
- describe formulation ingredients and their functions
- describe kit components and instructions
- describe kit instructions and forms
- describe incorporated patent applications
- describe examples of the invention

### EXAMPLE 1

- describe choroidal neovascularization (CNV) and its treatment challenges
- introduce photo-targeted nanoparticles (NP-[CPP]) for drug delivery
- evaluate NP-[CPP] in mice with laser-induced CNV

### EXAMPLE 2

- synthesize and characterize photo-targeted nanoparticles
- study nanoparticle uptake by cells
- measure rate of phototriggered release of DEACM-OH from NP-[CPP]

### EXAMPLE 3

- study nanoparticle uptake by human umbilical vein endothelial cells (HUVECs)
- determine optimal proportion of peptide-polymer conjugate for uptake
- confirm light-controlled micelle uptake by confocal microscopy

### EXAMPLE 4

- evaluate cytotoxicity and biocompatibility of treatments in HUVECs and in vivo

### EXAMPLE 5

- induce CNV in mice and inject fluorescently labeled nanoparticles
- evaluate nanoparticle accumulation in retinal blood vessels and laser-induced lesions
- study biodistribution of nanoparticles in organs

### EXAMPLE 6

- encapsulate doxorubicin in nanoparticles and evaluate in vitro release
- study therapeutic effects of phototriggered activation of nanoparticles in CNV
- evaluate treatment efficacy in mouse CNV model
- assess tissue reaction to treatment

### EXAMPLE 7

- synthesize polymer-peptide conjugates
- prepare polymeric nanoparticles
- characterize micelles by transmission electron microscopy
- characterize nanoparticles by dynamic light scattering
- measure photocleavage of DEACM-OH from NP-[CPP]
- perform flow cytometry
- perform confocal laser scanning microscopy
- analyze cytotoxicity
- determine loading efficiency of doxorubicin in NP-[CPP]
- analyze in vitro doxorubicin release
- perform animal studies
- perform fluorescence imaging of flat-mounted choroids
- perform biodistribution study
- perform histology

### EXAMPLE 8

- investigate effect of irradiation with blue LED light at lower intensity on NP accumulation in CNV lesions

### EXAMPLE 9

- investigate NP composition
- synthesize CPP-PEG(5K)-PLA
- prepare NP-AMF-CPP
- measure NP size
- study cellular uptake
- analyze flow cytometry results
- discuss NP structure importance
- illustrate quantification of HUVEC uptake
- describe FIG. 12
- conclude CPP-mediated cellular uptake

